Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

156TiP - An open-label, single-arm, phase II study evaluating the efficacy and safety of niraparib combined with radiotherapy and teriprizumab in patients with recurrent small cell lung cancer


03 Apr 2022


Poster Display session


Tumour Site

Small Cell Lung Cancer


Wei Zeng


Annals of Oncology (2022) 33 (suppl_2): S97-S104. 10.1016/annonc/annonc864


W. Zeng, C. Xie

Author affiliations

  • Zhongnan Hospital of Wuhan University, Wuhan/CN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 156TiP


Our previous basic research shows that radiotherapy combined with PARP inhibitors not only has direct antitumor effect in SCLC, but also can enhance antitumor immunity. At the same time, their combination can enhance the expression of PD-L1, which is considered to have a negative role in immune response. We found that triple therapy combined with PARP inhibitor and radiation plus anti-PD-1 can significantly enhance the antitumor effect and enhance the infiltration of cytotoxic T cells and memory T cells in SCLC model with immune function. More and more clinical evidence has confirmed the advantages of radiotherapy combined with immunity, especially in the treatment of inoperable locally advanced NSCLC. At present, some clinical studies have made breakthrough progress and successfully rewritten the guidelines.

Trial design

This study adopts a single arm design. It is planned to include 53 patients with extensive stage small cell lung cancer who have previously received 1-2-line treatment (including one systematic platinum containing treatment) and received niraparib combined with treprizumab and radiotherapy (SBRT). The main purpose of this study was to explore the efficacy and safety of niraparib combined with treprizumab and radiotherapy in the treatment of extensive small cell lung cancer who had previously received 1-2 lines of therapy (including one systematic platinum-containing therapy). The patients entered the trial period immediately after signing the informed consent. The first cycle: first, they receive niraparib (200mg QD), selected non target lesions suitable for SBRT for radiotherapy (8Gy x 3f) on the fourth day, and added treprizumab immunotherapy 240mg intravenous drip q3w on the seventh day. Start of the second cycle: continue to receive the combined treatment of treprizumab (240mg D1 q3w) + niraparib (200mg QD), one cycle every 21 days until the disease progresses, and the maximum use time is 2 years. The previous radiotherapy site cannot be used as the radiotherapy focus again, and the imaging evaluation is carried out according to RECIST 1.1 standard.

Clinical trial identification

NCT05162196; Release date: March 2025.

Legal entity responsible for the study

The authors.


Zailaboratory. Junshi Biosciences.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.